Arizona funds $5M ibogaine study for brain injuries

The Arizona Department of Health Services has allocated a $5 million grant to the Barrow Neurological Institute to investigate ibogaine as a treatment for post-traumatic stress disorder (PTSD) and brain injuries. This initiative, announced on August 18, 2026, aims to explore the potential of ibogaine, a psychoactive compound, in alleviating symptoms associated with traumatic brain injuries, according to the institute.

What the study involves

The research, conducted in collaboration with Arizona State University, will involve 40 participants experiencing chronic symptoms from traumatic brain injuries. The study will assess whether ibogaine can significantly improve their symptoms or quality of life. Participants will be divided into two groups: one receiving ibogaine and the other a placebo. Both participants and researchers will be aware of who receives the actual drug, as per a press release from Barrow Neurological Institute.

Regulatory context

Ibogaine is currently classified as a Schedule 1 controlled substance in the United States, alongside drugs like heroin and LSD. This classification has historically driven Americans seeking ibogaine treatment to clinics abroad, such as in Mexico. Despite this, interest in psychedelic treatments is growing in the U.S., with notable support from figures like former Senator Kyrsten Sinema and Health and Human Services Secretary Robert F. Kennedy Jr.

Funding and political support

The $5 million funding was included in Arizona's state budget in 2025, following advocacy by Sinema and testimonies from veterans who reported positive outcomes from ibogaine treatments. This funding aligns with broader national interest, as exemplified by an executive order signed by President Donald Trump in April, which allocated at least $50 million for state partnerships to study psychedelics for mental health treatment.

Why it matters

The study could pave the way for new therapeutic options for individuals suffering from the long-term effects of neurological injuries. As Susan Criswell, chief medical officer for clinical research at Barrow, highlighted, about half of those with traumatic brain injuries experience incomplete recovery or persistent symptoms after six months. Exploring ibogaine's potential could offer hope for improved recovery outcomes.

This research is part of a broader trend of increasing interest in psychedelic therapies within the U.S., reflecting a shift in how mental health and neurological conditions might be treated in the future.